By independently manipulating the lifespan of worms and one of its purported biomarkers, namely, the cessation of vigorous movement (CVM), investigators at the Center for Genomic Regulation (CRG) in Barcelona have demonstrated that the two are driven by partly independent processes.
Transcenta Holding Ltd. has received IND clearance from the FDA for TST-004, its best-in-class, humanized monoclonal antibody targeting mannose-binding protein-associated serine protease 2 (MASP2), for IgA nephropathy (IgAN).
Additional early-stage research and drug discovery news in brief, from: CSL, Elicio Therapeutics, Enzolytics, Innovation Pharmaceuticals, Lumen Bioscience, Nanology.
Lifearc and Provincial Health Services Authority (PHSA) have presented 7-morpholino-l,6-naphthyridin-5-yl derivatives acting as DNA-dependent protein kinase (DNA-PK) inhibitors reported to be useful for the treatment of cancer.
Gilead Sciences Inc. has patented glucagon-like peptide 1 (GLP-1) receptor agonists reported to be useful for the treatment of type 2 diabetes, obesity, prediabetes, atherosclerosis, metabolic syndrome, stroke, nonalcoholic steatohepatitis and renal disorders, among other disorders.
Blueprint Medicines Corp. has divulged new EGFR mutant inhibitors, particularly EGFR L858R mutant and EGFR del746-750 mutant, reported to be useful for the treatment of non-small-cell lung cancer.
Latigo Biotherapeutics Inc. and Lieber Institute Inc. have synthesized new methyl-substituted pyridine and pyridazine compounds acting as sodium channel protein type 10 subunit α (Nav1.8) channel blockers reported to be useful for the treatment of pain, arthritis, atherosclerosis, irritable bowel syndrome, cancer and psychiatric, respiratory and neurological disorders, among other disorders.
Dice Molecules SV LLC has divulged new integrin αv/β1 and/or integrin αv/β6 antagonists reported to be useful for the treatment of fibrosis, rheumatoid arthritis, diabetic nephropathy, nonalcoholic steatohepatitis, focal segmental glomerulosclerosis, primary biliary cholangitis and cancer.
Intravacc BV has been awarded a contract by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), for the development of a prophylactic intranasal vaccine against Neisseria gonorrhoeae (NG), the cause of the sexually transmitted disease gonorrhea.
RSS
